Clinical pathways for pancreatic neuroendocrine tumors

Angela Alistar, Max Sung, Michelle Kim, Randall F. Holcombe

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Pancreatic neuroendocrine tumors (PNETs) represent a group of diseases that pose diagnostic and therapeutic challenges due to their clinical and pathological heterogeneity as well as the limited number of patients available for clinical trials. Over the last couple of decades, a major progress in understanding tumor biology led to the discovery of new potential targets for the medical treatment of these tumors. Discussion: There are numerous novel targeted agents in various stages of preclinical and clinical development that offer considerable promise as monotherapy or combination therapy for PNETs. The question of whether traditional clinical research methods are appropriate for the development of novel, targeted anticancer agents has been the subject of many discussions. Major challenges include identifying a valid target, the most effective agent within a target class, the right subset of population to benefit from the drug, and the most appropriate setting to use the drug. As new agents emerge, oncologists are faced with making clinical decisions sometimes before having a high level of evidence. In this review, we attempt to address some of the management steps involved in treating patients with pancreatic neuroendocrine tumors, particularly well to moderately differentiated tumors. The purpose of this review is to offer a therapeutic sequence including surgery, liver-directed therapy, chemotherapy, and targeted therapy for this disease.

Original languageEnglish (US)
Pages (from-to)532-540
Number of pages9
JournalJournal of Gastrointestinal Cancer
Volume43
Issue number4
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Critical Pathways
Neuroendocrine Tumors
Therapeutics
Neoplasms
Pharmaceutical Preparations
Antineoplastic Agents
Clinical Trials
Drug Therapy
Liver
Research
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

Alistar, Angela ; Sung, Max ; Kim, Michelle ; Holcombe, Randall F. / Clinical pathways for pancreatic neuroendocrine tumors. In: Journal of Gastrointestinal Cancer. 2012 ; Vol. 43, No. 4. pp. 532-540.
@article{5ea6f2087c4843698e6591b738301b37,
title = "Clinical pathways for pancreatic neuroendocrine tumors",
abstract = "Background: Pancreatic neuroendocrine tumors (PNETs) represent a group of diseases that pose diagnostic and therapeutic challenges due to their clinical and pathological heterogeneity as well as the limited number of patients available for clinical trials. Over the last couple of decades, a major progress in understanding tumor biology led to the discovery of new potential targets for the medical treatment of these tumors. Discussion: There are numerous novel targeted agents in various stages of preclinical and clinical development that offer considerable promise as monotherapy or combination therapy for PNETs. The question of whether traditional clinical research methods are appropriate for the development of novel, targeted anticancer agents has been the subject of many discussions. Major challenges include identifying a valid target, the most effective agent within a target class, the right subset of population to benefit from the drug, and the most appropriate setting to use the drug. As new agents emerge, oncologists are faced with making clinical decisions sometimes before having a high level of evidence. In this review, we attempt to address some of the management steps involved in treating patients with pancreatic neuroendocrine tumors, particularly well to moderately differentiated tumors. The purpose of this review is to offer a therapeutic sequence including surgery, liver-directed therapy, chemotherapy, and targeted therapy for this disease.",
author = "Angela Alistar and Max Sung and Michelle Kim and Holcombe, {Randall F.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s12029-012-9397-y",
language = "English (US)",
volume = "43",
pages = "532--540",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
number = "4",

}

Clinical pathways for pancreatic neuroendocrine tumors. / Alistar, Angela; Sung, Max; Kim, Michelle; Holcombe, Randall F.

In: Journal of Gastrointestinal Cancer, Vol. 43, No. 4, 01.12.2012, p. 532-540.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical pathways for pancreatic neuroendocrine tumors

AU - Alistar, Angela

AU - Sung, Max

AU - Kim, Michelle

AU - Holcombe, Randall F.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Pancreatic neuroendocrine tumors (PNETs) represent a group of diseases that pose diagnostic and therapeutic challenges due to their clinical and pathological heterogeneity as well as the limited number of patients available for clinical trials. Over the last couple of decades, a major progress in understanding tumor biology led to the discovery of new potential targets for the medical treatment of these tumors. Discussion: There are numerous novel targeted agents in various stages of preclinical and clinical development that offer considerable promise as monotherapy or combination therapy for PNETs. The question of whether traditional clinical research methods are appropriate for the development of novel, targeted anticancer agents has been the subject of many discussions. Major challenges include identifying a valid target, the most effective agent within a target class, the right subset of population to benefit from the drug, and the most appropriate setting to use the drug. As new agents emerge, oncologists are faced with making clinical decisions sometimes before having a high level of evidence. In this review, we attempt to address some of the management steps involved in treating patients with pancreatic neuroendocrine tumors, particularly well to moderately differentiated tumors. The purpose of this review is to offer a therapeutic sequence including surgery, liver-directed therapy, chemotherapy, and targeted therapy for this disease.

AB - Background: Pancreatic neuroendocrine tumors (PNETs) represent a group of diseases that pose diagnostic and therapeutic challenges due to their clinical and pathological heterogeneity as well as the limited number of patients available for clinical trials. Over the last couple of decades, a major progress in understanding tumor biology led to the discovery of new potential targets for the medical treatment of these tumors. Discussion: There are numerous novel targeted agents in various stages of preclinical and clinical development that offer considerable promise as monotherapy or combination therapy for PNETs. The question of whether traditional clinical research methods are appropriate for the development of novel, targeted anticancer agents has been the subject of many discussions. Major challenges include identifying a valid target, the most effective agent within a target class, the right subset of population to benefit from the drug, and the most appropriate setting to use the drug. As new agents emerge, oncologists are faced with making clinical decisions sometimes before having a high level of evidence. In this review, we attempt to address some of the management steps involved in treating patients with pancreatic neuroendocrine tumors, particularly well to moderately differentiated tumors. The purpose of this review is to offer a therapeutic sequence including surgery, liver-directed therapy, chemotherapy, and targeted therapy for this disease.

UR - http://www.scopus.com/inward/record.url?scp=84876291883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876291883&partnerID=8YFLogxK

U2 - 10.1007/s12029-012-9397-y

DO - 10.1007/s12029-012-9397-y

M3 - Review article

C2 - 22661335

AN - SCOPUS:84876291883

VL - 43

SP - 532

EP - 540

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

IS - 4

ER -